Replies to post #72 on Affymetrix Inc. (AFFX)

[surf1944]

6:12PM Affymetrix reports that China clears its first microarray platform for in vitro diagnostics to accelerate personalized medicine (AFFX) 4.63 +0.05 : Co announced that its GeneChip? System 3000Dx v.2 (GCS 3000Dx v.2) has been approved by China's State Food and Drug Administration (SFDA) for in vitro diagnostic use. The GCS 3000Dx v.2 is the first microarray instrument system to be granted SFDA registration for array-based diagnostics for enabling personalized medicine. China has more than 2,000 clinical centers that will now have access to the only SFDA-cleared microarray platform for clinical testing. The molecular diagnostic market in China is the fastest growing in the world and represents a significant growth opportunity for Affymetrix in Asia.